Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis, Adds New Chief Business Officer Portfolio News / By Karina Tin April 25th, 2022
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022 Portfolio News / By Karina Tin April 20, 2022
ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting Portfolio News / By Karina Tin April 12, 2022
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting Portfolio News / By Karina Tin April 8, 2022
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio Portfolio News / By Karina Tin April 8, 2022
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin April 7, 2022
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors Portfolio News / By Karina Tin April 5, 2022
eFFECTOR Therapeutics Announces Transition in Clinical Leadership Portfolio News / By Karina Tin April 4, 2022
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy Portfolio News / By Karina Tin April 1, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors Portfolio News / By Karina Tin March 31, 2022
